Checkpoint Therapeutics, Inc. (CKPT): Stock Offering News

CKPT – Proposes to offer and sell shares of its common stock in an underwritten public offering; size not disclosed.


Key Facts Surrounding This News Item


  • CKPT had returned +44.33% year-to-date leading up to today’s news, versus a +2.26% return from the benchmark S&P 500 during the same period.

More Info About Checkpoint Therapeutics, Inc. (CKPT)


Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. View our full CKPT ticker page with ratings, news, and more.

CKPT at a Glance

CKPT Current POWR Rating™
Overall POWR Rating™
CKPT Current Price $2.15 4.66%
More CKPT Ratings, Data, and News

CKPT Price Reaction

The day of this event (Mar. 7, 2018)
CKPT Closing Price$5.34 4.64%
CKPT Volume176,100
515.02% from avg
Leading up to this event
CKPT 1-mo return38.27%
After this event
CKPT 1-day return19.15%
CKPT 3-day return15.46%
CKPT 5-day return19.66%

CKPT Price Chart


The Top Stocks For 2019

More Checkpoint Therapeutics, Inc. (CKPT) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CKPT News
Page generated in 0.8802 seconds.